Global perceptions of the current and future impacts of COVID-19 on hereditary angioedema management

Vesna Grivcheva-Panovska1, Timothy J Craig2, Hilary Longhurst3

  • 1From the Public Health Institution University Clinic of Dermatology, School of Medicine, University Saints Cyril and Methodius, Skopje, North Macedonia.

Insights

The COVID-19 pandemic has negatively impacted hereditary angioedema (HAE) care globally, with patients and healthcare professionals expecting long-term effects. Telehealth adoption increased but was more successful in high-income nations, highlighting disparities.

Area of Science:

  • Medical Care
  • Global Health
  • Chronic Disease Management

Background:

  • The COVID-19 pandemic significantly disrupted healthcare services worldwide, complicating the management of chronic conditions like hereditary angioedema (HAE).
  • HAE management requires consistent medical care and prophylactic medication, which were challenged by resource strain and social distancing during the pandemic.
  • Limited data existed on HAE care provision during the COVID-19 era.

Purpose of the Study:

  • To assess the global impact of the COVID-19 pandemic on hereditary angioedema (HAE) medical care from patient and healthcare professional (HCP) viewpoints.
  • To understand the anticipated future effects of the pandemic on HAE care.
  • To identify disparities in HAE care perceptions based on economic and geographic factors.

Main Methods:

  • Conducted two parallel online global surveys.
  • Collected perspectives from both HAE patients and healthcare professionals (HCPs).
  • Focused on the impact of COVID-19 on HAE medical care and future expectations.

Main Results:

  • Both patients and HCPs reported reduced availability of HAE medical care due to the pandemic, with expectations of continued restrictions.
  • Telehealth utilization has risen globally, though its implementation was more effective in high-income countries.
  • A significant portion of patients and HCPs anticipate negative impacts on HAE care lasting well beyond the pandemic.

Conclusions:

  • Hereditary angioedema (HAE) care is expected to face prolonged negative consequences from the COVID-19 pandemic.
  • Disparities in healthcare access and technological infrastructure may worsen challenges in low- and middle-income countries.
  • Establishing global support systems and infrastructure is crucial to assist non-high-income nations in managing HAE care during and after the pandemic.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
44
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
808
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
661
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
29
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
85
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.7K